Macrophages: A double-edged sword in experimental autoimmune encephalomyelitis

Immunology Letters

Volumn 160, Issue 1, 2014, Pages 17-

  Jiang, Zhilong ^a   Jiang, Jack X ^b   Zhang, Guang Xian ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis; Macrophages; Multiple sclerosis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBON TETRACHLORIDE; CHEMOKINE RECEPTOR CCR4; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 4; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NITRIC OXIDE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; ENVIRONMENTAL FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEREDITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TISSUE REPAIR;

EID: 84940257897     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.03.006     Document Type: Review

References (77)

1. Hickey W.F. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol 1999, 98:37-44.
2. Banwell B., Bar-Or A., Arnold D.L., Sadovnick D., Narayanan S., McGowan M., et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011, 10:436-445.
3. Lassmann H., Bruck W., Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001, 7:115-121.
4. Turrin N.P. Central nervous system Toll-like receptor expression in response to Theiler's murine encephalomyelitis virus-induced demyelination disease in resistant and susceptible mouse strains. Virol J 2008, 5:154.
5. Almolda B., Gonzalez B., Castellano B. Antigen presentation in EAE: role of microglia, macrophages and dendritic cells. Front Biosci 2011, 16:1157-1171.
6. Bailey S.L., Schreiner B., McMahon E.J., Miller S.D. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007, 8:172-180.
7. Jiang H.R., Milovanovic M., Allan D., Niedbala W., Besnard A.G., Fukada S.Y., et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 2012, 42:1804-1814.
8. Jiang Z., Li H., Fitzgerald D.C., Zhang G.X., Rostami A. MOG(35-55) i.v. suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways. Eur J Immunol 2009, 39:789-799.
9. Xiao B.G., Ma C.G., Xu L.Y., Link H., Lu C.Z. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol Immunol 2008, 45:1191-1196.
10. Lavasani S., Dzhambazov B., Nouri M., Fak F., Buske S., Molin G., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE 2010, 5:e9009.
11. Rawji K.S., Yong V.W. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol 2013, 2013:948976.
12. Abourbeh G., Theze B., Maroy R., Dubois A., Brulon V., Fontyn Y., et al. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18kDa translocator protein radioligand [(1)(8)F]DPA-714. J Neurosci 2012, 32:5728-5736.
13. Butovsky O., Jedrychowski M.P., Moore C.S., Cialic R., Lanser A.J., Gabriely G., et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 2014, 17:131-143.
14. Miron V.E., Boyd A., Zhao J.W., Yuen T.J., Ruckh J.M., Shadrach J.L., et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013, 16:1211-1218.
15. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013, 19:1264-1272.
16. Saederup N., Cardona A.E., Croft K., Mizutani M., Cotleur A.C., Tsou C.L., et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS ONE 2010, 5:e13693.
17. Trebst C., Sorensen T.L., Kivisakk P., Cathcart M.K., Hesselgesser J., Horuk R., et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001, 159:1701-1710.
18. Veremeyko T., Starossom S.C., Weiner H.L., Ponomarev E.D. Detection of microRNAs in microglia by real-time PCR in normal CNS and during neuroinflammation. J Vis Exp 2012, 10:3791-4097.
19. Aloisi F., Ria F., Penna G., Adorini L. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 1998, 160:4671-4680.
20. Ponomarev E.D., Veremeyko T., Barteneva N., Krichevsky A.M., Weiner H.L. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011, 17:64-70.
21. Heppner F.L., Greter M., Marino D., Falsig J., Raivich G., Hovelmeyer N., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005, 11:146-152.
22. Li J., Gran B., Zhang G.X., Ventura E.S., Siglienti I., Rostami A., et al. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 2003, 215:95-103.
23. Ponomarev E.D., Shriver L.P., Maresz K., Pedras-Vasconcelos J., Verthelyi D., Dittel B.N. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007, 178:39-48.
24. Oleszak E.L., Zaczynska E., Bhattacharjee M., Butunoi C., Legido A., Katsetos C.D. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol 1998, 5:438-445.
25. Cox G.M., Kithcart A.P., Pitt D., Guan Z., Alexander J., Williams J.L., et al. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. J Immunol 2013, 191:1043-1054.
26. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
27. Dheen S.T., Kaur C., Ling E.A. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007, 14:1189-1197.
28. Forde E.A., Dogan R.N., Karpus W.J. CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function. J Neuroimmunol 2011, 236:17-26.
29. Karpus W.J., Kennedy K.J. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997, 62:681-687.
30. Brini E., Ruffini F., Bergami A., Brambilla E., Dati G., Greco B., et al. Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss. J Neuroimmunol 2009, 209:33-39.
31. Larsen P.H., Wells J.E., Stallcup W.B., Opdenakker G., Yong V.W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003, 23:11127-11135.
32. Coull J.A., Beggs S., Boudreau D., Boivin D., Tsuda M., Inoue K., et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438:1017-1021.
33. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci 1996, 16:2508-2521.
34. Herx L.M., Rivest S., Yong V.W. Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J Immunol 2000, 165:2232-2239.
35. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007, 13:935-943.
36. Aguzzi A., Barres B.A., Bennett M.L. Microglia: scapegoat, saboteur, or something else. Science 2013, 339:156-161.
37. Ousman S.S., Kubes P. Immune surveillance in the central nervous system. Nat Neurosci 2012, 15:1096-1101.
38. Dogan R.N., Long N., Forde E., Dennis K., Kohm A.P., Miller S.D., et al. CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function. J Leukoc Biol 2011, 89:93-104.
39. Columba-Cabezas S., Serafini B., Ambrosini E., Sanchez M., Penna G., Adorini L., et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 2002, 130:10-21.
40. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., Dereuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005, 142:481-489.
41. Hendriks J.J., Teunissen C.E., de Vries H.E., Dijkstra C.D. Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005, 48:185-195.
42. Neumann H., Kotter M.R., Franklin R.J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132:288-295.
43. Chang C.P., Su Y.C., Hu C.W., Lei H.Y. TLR2-dependent selective autophagy regulates NF-kappaB lysosomal degradation in hepatoma-derived M2 macrophage differentiation. Cell Death Differ 2013, 20:515-523.
44. Chang C.P., Su Y.C., Lee P.H., Lei H.Y. Targeting NFKB by autophagy to polarize hepatoma-associated macrophage differentiation. Autophagy 2013, 9:619-621.
45. Moreira A.J., Fraga C., Alonso M., Collado P.S., Zetller C., Marroni C., et al. Quercetin prevents oxidative stress and NF-kappaB activation in gastric mucosa of portal hypertensive rats. Biochem Pharmacol 2004, 68:1939-1946.
46. Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
47. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 2011, 17:2-15.
48. Liu C., Li Y., Yu J., Feng L., Hou S., Liu Y., et al. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS ONE 2013, 8:e54841.
49. Girvin A.M., Dal Canto M.C., Miller S.D. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J Autoimmun 2002, 18:83-94.
50. Imler T.J., Petro T.M. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009, 9:134-143.
51. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29:13435-13444.
52. Shin T., Kim S., Moon C., Wie M., Kim H. Aminoguanidine-induced amelioration of autoimmune encephalomyelitis is mediated by reduced expression of inducible nitric oxide synthase in the spinal cord. Immunol Invest 2000, 29:233-241.
53. Berard J.L., Kerr B.J., Johnson H.M., David S. Differential expression of SOCS1 in macrophages in relapsing-remitting and chronic EAE and its role in disease severity. Glia 2010, 58:1816-1826.
54. Shin T., Ahn M., Matsumoto Y. Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: recent insights from macrophages. Anat Cell Biol 2012, 45:141-148.
55. Tierney J.B., Kharkrang M., La Flamme A.C. Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis. Immunol Cell Biol 2009, 87:235-240.
56. Denney L., Kok W.L., Cole S.L., Sanderson S., McMichael A.J., Ho L.P. Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome. J Immunol 2012, 189:551-557.
57. Keating P., O'Sullivan D., Tierney J.B., Kenwright D., Miromoeini S., Mawasse L., et al. Protection from EAE by IL-4Ralpha(-/-) macrophages depends upon T regulatory cell involvement. Immunol Cell Biol 2009, 87:534-545.
58. Veremeyko T., Siddiqui S., Sotnikov I., Yung A., Ponomarev E.D. IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation. PLoS ONE 2013, 8:e81774.
59. Chhor V., Le Charpentier T., Lebon S., Ore M.V., Celador I.L., Josserand J., et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 2013, 32:70-85.
60. Elcombe S.E., Naqvi S., Van Den Bosch M.W., MacKenzie K.F., Cianfanelli F., Brown G.D., et al. Dectin-1 regulates IL-10 production via a MSK1/2 and CREB dependent pathway and promotes the induction of regulatory macrophage markers. PLoS ONE 2013, 8:e60086.
61. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
62. Ogawa K., Funaba M., Chen Y., Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 2006, 177:6787-6794.
63. Furlan R., Poliani P.L., Galbiati F., Bergami A., Grimaldi L.M., Comi G., et al. Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum Gene Ther 1998, 9:2605-2617.
64. Dimitrijevic M., Mitic K., Kustrimovic N., Vujic V., Stanojevic S. NPY suppressed development of experimental autoimmune encephalomyelitis in Dark Agouti rats by disrupting costimulatory molecule interactions. J Neuroimmunol 2012, 245:23-31.
65. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76:509-513.
66. Katakura T., Miyazaki M., Kobayashi M., Herndon D.N., Suzuki F. CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 2004, 172:1407-1413.
67. King I.L., Dickendesher T.L., Segal B.M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009, 113:3190-3197.
68. Zhang Z., Zhang Z.Y., Wu Y., Schluesener H.J. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 2012, 221:140-150.
69. Wu M., Nissen J.C., Chen E.I., Tsirka S.E. Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis. PLoS ONE 2012, 7:e34933.
70. Jung S., Siglienti I., Grauer O., Magnus T., Scarlato G., Toyka K. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004, 148:63-73.
71. Linker R.A., Luhder F., Kallen K.J., Lee D.H., Engelhardt B., Rose-John S., et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J Neuroimmunol 2008, 205:64-72.
72. Linker R.A., Weller C., Luhder F., Mohr A., Schmidt J., Knauth M., et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol 2008, 211:397-406.
73. Inoue M., Williams K.L., Oliver T., Vandenabeele P., Rajan J.V., Miao E.A., et al. Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 2012, 5:ra38.
74. Crielaard B.J., Lammers T., Morgan M.E., Chaabane L., Carboni S., Greco B., et al. Macrophages and liposomes in inflammatory disease: friends or foes. Int J Pharm 2011, 416:499-506.
75. Galligan C.L., Pennell L.M., Murooka T.T., Baig E., Majchrzak-Kita B., Rahbar R., et al. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult Scler 2010, 16:1458-1473.
76. Ponomarev E.D., Veremeyko T., Weiner H.L. MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia 2013, 61:91-103.
77. Makeyev E.V., Zhang J., Carrasco M.A., Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007, 27:435-448.